Sage Therapeutics Stock Price, News & Analysis (NASDAQ:SAGE)

$85.68 0.01 (0.01 %)
(As of 11/18/2017 03:46 AM ET)
Previous Close$85.68
Today's Range$87.19 - $85.40
52-Week Range$44.55 - $99.80
Volume755,993 shs
Average Volume545,248 shs
Market Capitalization$3.22 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.79

About Sage Therapeutics (NASDAQ:SAGE)

Sage Therapeutics logoSAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company's lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor. The Company's next-generation product candidates, SAGE-217 and SAGE-689, also target the GABAA receptor system. The Company is focused on developing drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The Company's chemistry platform is focused on the chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or N-Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA) receptors.


Industry, Sector and Symbol:
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Sector: Biotechnology & Medical Research - NEC
  • Symbol: NASDAQ:SAGE
  • CUSIP: N/A
  • Web: www.sagerx.com
Debt:
  • Current Ratio: 4.98%
  • Quick Ratio: 4.98%
Sales & Book Value:
  • Annual Sales: N/A
  • Price / Sales: N/A
  • Book Value: $5.33 per share
  • Price / Book: 16.08
Profitability:
  • Trailing EPS: ($6.87)
  • Net Income: ($158,980,000.00)
  • Return on Equity: -89.46%
  • Return on Assets: -78.94%
Misc:
  • Employees: 135
  • Outstanding Shares: 41,050,000
 

Frequently Asked Questions for Sage Therapeutics (NASDAQ:SAGE)

What is Sage Therapeutics' stock symbol?

Sage Therapeutics trades on the NASDAQ under the ticker symbol "SAGE."

How were Sage Therapeutics' earnings last quarter?

Sage Therapeutics, Inc. (NASDAQ:SAGE) issued its quarterly earnings results on Thursday, November, 2nd. The biopharmaceutical company reported ($1.97) earnings per share for the quarter, topping the Zacks' consensus estimate of ($1.98) by $0.01. The business's revenue was up .0% compared to the same quarter last year. View Sage Therapeutics' Earnings History.

Where is Sage Therapeutics' stock going? Where will Sage Therapeutics' stock price be in 2017?

14 brokerages have issued 1 year target prices for Sage Therapeutics' shares. Their predictions range from $81.00 to $145.00. On average, they anticipate Sage Therapeutics' stock price to reach $105.71 in the next twelve months. View Analyst Ratings for Sage Therapeutics.

What are Wall Street analysts saying about Sage Therapeutics stock?

Here are some recent quotes from research analysts about Sage Therapeutics stock:

  • 1. Needham & Company LLC analysts commented, "We hosted a call with expert Dr. Peter Kaplan to review the super refractory status epilepticus (SRSE) space and expectations for Sage Therapeutics’ drug IV brexanolone, which is currently being evaluated in the ongoing pivotal Phase 3 STATUS trial (results expected 3Q17). Dr. Kaplan has been practicing at Johns Hopkins for 30 years and his academic experience has been mostly clinical in nature. He is currently based at Johns Hopkins Bayview Medical Center and is consulted throughout the hospital for input regarding EEGs and for optimal management of status epilepticus. Below we highlight our key takeaways from the call." (6/13/2017)
  • 2. BMO Capital Markets analysts commented, "We spoke with two leading psychiatrists who agreed that these data, while early, look great; they were particularly impressed with the magnitude of effect, early onset, strong remission rate, and overall safety for SAGE-217 in MDD. This profile is considered the 'holy grail' in treating depression. The physicians were also very optimistic regarding the prospects for SAGE-217 in a placebo-controlled trial for MDD given the large effect size in the open-label (one said 75-80% chance of success)' We are now including risk-adjusted sales for SAGE-217 in MDD of $25mn in 2021 ramping up to $325mn in 2027. We partially offset that with some increased expenses; the net result was that our EPS changed by $(0.51)-4.04 in 2017-27, and our target goes to $82 from $68." (2/22/2017)
  • 3. Chardan Capital analysts commented, "Yesterday, Sage Therapeutics announced encouraging top-line phase II results from its open label clinical trial of orally-administered SAGE-217 for major depressive disorder (MDD). Our discussions yesterday with industry participants in the depression space suggested a decidedly positive view of the SAGE-217 data. We now note that the SAGE-217 result follows what to us, in our 12 July 2016 research, was "potentially clear, positive" phase II data for IV SAGE-547 in severe postpartum depression (PPD). Although our 20 July 2016 questions on SAGE-547 remain unanswered, we are reassured by the granting of Breakthrough Therapy Designation (BTD) for SAGE-547 by the FDA and PRIME Designation by EMA, which both likely independently considered the issues we raised. Our initial 24 May 2016 bearish view on Sage was based largely on our expectations of phase III data for SAGE-547 in super-refractory status epilepticus (SRSE), which were originally due to read out in 2H16. The timing of the data has since moved to 1H17, exposing any SAGE-547 SRSE bear thesis to the upside potential surrounding SAGE-217 in MDD, and more limited potential of SAGE-547 in PPD. Indeed, we now see upside risk elsewhere in Sage and thereby upgrade from Sell to Neutral, raising our PT from $18 to $60." (2/14/2017)
  • 4. Cowen and Company analysts commented, "Today SAGE announced positive top-line results from its Ph2 OL trial of SAGE-217 in." (2/13/2017)
  • 5. Canaccord Genuity analysts commented, "We are encouraged by NDRM’s progress on its multiple development programs and continue to view the company’s approach to treating Parkinson’s disease as potentially paradigm-shifting. NDRM recently had an end of Ph2 meeting with the FDA to discuss ND0612 and has been allowed to move forward with PK equivalency in the US as opposed to doing a Ph3 efficacy trial. Additionally, NDRM announced positive top-line data from a pilot PK trial of ND0701 last week." (12/6/2016)

Who are some of Sage Therapeutics' key competitors?

Who are Sage Therapeutics' key executives?

Sage Therapeutics' management team includes the folowing people:

  • Kevin P. Starr, Independent Chairman of the Board (Age 54)
  • Jeffrey M. Jonas M.D., President, Chief Executive Officer, Director (Age 64)
  • Kimi E. Iguchi, Chief Financial Officer, Treasurer (Age 53)
  • Anne Marie Cook, Senior Vice President, General Counsel (Age 54)
  • Amy Schacterle Ph.D., Senior Vice President - Regulatory Affairs and Quality Assurance
  • Christopher Silber, Senior Vice President - Clinical Development
  • Albert J. Robichaud Ph.D., Chief Scientific Officer (Age 54)
  • Frank Sanders, Vice President of Sales and Marketing
  • Paul Hodgkins, Vice President - Health Economics and Outcomes Research and Value Demonstration
  • Thomas D. Anderson, Chief Commercial Strategy Officer (Age 60)

Who owns Sage Therapeutics stock?

Sage Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Bank of New York Mellon Corp (7.22%), Oak Ridge Investments LLC (1.96%), Eagle Asset Management Inc. (1.67%), Pictet Asset Management Ltd. (1.01%), Victory Capital Management Inc. (0.89%) and Amundi Pioneer Asset Management Inc. (0.48%). Company insiders that own Sage Therapeutics stock include Albert Robichaud, Kevin P Starr, Kimi Iguchi and Stephen Kanes. View Institutional Ownership Trends for Sage Therapeutics.

Who sold Sage Therapeutics stock? Who is selling Sage Therapeutics stock?

Sage Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Emerald Advisers Inc. PA, Pictet Asset Management Ltd., Emerald Mutual Fund Advisers Trust, Eagle Asset Management Inc., Nicholas Investment Partners LP, Essex Investment Management Co. LLC and Clarius Group LLC. View Insider Buying and Selling for Sage Therapeutics.

Who bought Sage Therapeutics stock? Who is buying Sage Therapeutics stock?

Sage Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, New York State Common Retirement Fund, Artal Group S.A., Westpac Banking Corp, Wells Fargo & Company MN, Alyeska Investment Group L.P., Amundi Pioneer Asset Management Inc. and Cowen Inc.. View Insider Buying and Selling for Sage Therapeutics.

How do I buy Sage Therapeutics stock?

Shares of Sage Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sage Therapeutics' stock price today?

One share of Sage Therapeutics stock can currently be purchased for approximately $85.68.

How big of a company is Sage Therapeutics?

Sage Therapeutics has a market capitalization of $3.22 billion. The biopharmaceutical company earns ($158,980,000.00) in net income (profit) each year or ($6.87) on an earnings per share basis. Sage Therapeutics employs 135 workers across the globe.

How can I contact Sage Therapeutics?

Sage Therapeutics' mailing address is 215 1st St, CAMBRIDGE, MA 02142-1213, United States. The biopharmaceutical company can be reached via phone at +1-617-2998380 or via email at ir@sagerx.com.


MarketBeat Community Rating for Sage Therapeutics (NASDAQ SAGE)

Community Ranking:  3.7 out of 5 (star star star)
Outperform Votes:  344 (Vote Outperform)
Underperform Votes:  120 (Vote Underperform)
Total Votes:  464
MarketBeat's community ratings are surveys of what our community members think about Sage Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Sage Therapeutics (NASDAQ:SAGE)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 1 Hold Rating, 13 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.93)
Consensus Price Target: $105.71 (23.38% upside)

Consensus Price Target History for Sage Therapeutics (NASDAQ:SAGE)

Price Target History for Sage Therapeutics (NASDAQ:SAGE)

Analysts' Ratings History for Sage Therapeutics (NASDAQ:SAGE)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/17/2017BMO Capital MarketsReiterated RatingOutperform$85.67 -> $112.00N/AView Rating Details
11/16/2017Bank of America CorporationLower Price TargetBuy$103.00 -> $101.00N/AView Rating Details
11/15/2017SunTrust Banks, Inc.Boost Price TargetBuy -> Positive$116.00N/AView Rating Details
11/10/2017Needham & Company LLCBoost Price TargetBuy -> Buy$86.00 -> $100.00N/AView Rating Details
11/10/2017Chardan CapitalUpgradeNeutral -> Buy$60.00 -> $140.00N/AView Rating Details
11/9/2017Raymond James Financial, Inc.Boost Price TargetBuy$109.00N/AView Rating Details
11/9/2017Stifel NicolausBoost Price TargetBuy$91.00 -> $105.00N/AView Rating Details
11/9/2017Royal Bank Of CanadaBoost Price TargetOutperform$145.00N/AView Rating Details
11/9/2017Leerink SwannBoost Price TargetOutperform -> Positive$85.00 -> $123.00N/AView Rating Details
10/6/2017Goldman Sachs Group, Inc. (The)Reiterated RatingBuy -> Buy$87.00N/AView Rating Details
9/12/2017Canaccord GenuityLower Price TargetBuy$110.00 -> $81.00HighView Rating Details
9/12/2017J P Morgan Chase & CoLower Price TargetOverweight$99.00 -> $85.00HighView Rating Details
9/12/2017Cowen and CompanyLower Price TargetOutperform$100.00 -> $90.00MediumView Rating Details
8/4/2017HC WainwrightBoost Price TargetNeutral$86.00HighView Rating Details
7/15/2016William BlairReiterated RatingOutperform$75.00N/AView Rating Details
3/11/2016Lake Street CapitalInitiated CoverageBuy$90.00N/AView Rating Details
(Data available from 11/19/2015 forward)

Earnings

Earnings History and Estimates Chart for Sage Therapeutics (NASDAQ:SAGE)

Earnings by Quarter for Sage Therapeutics (NASDAQ:SAGE)

Earnings History by Quarter for Sage Therapeutics (NASDAQ SAGE)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2017Q3 2017($1.98)($1.97)ViewN/AView Earnings Details
8/3/2017Q2 2017($1.63)($1.88)ViewListenView Earnings Details
5/9/2017Q1 2017($1.61)($1.52)ViewListenView Earnings Details
2/23/2017Q4 2016($1.17)($1.50)ViewN/AView Earnings Details
11/3/2016Q316($1.10)($1.15)ViewN/AView Earnings Details
8/9/2016Q216($1.02)($1.08)ViewN/AView Earnings Details
5/5/2016Q1($0.98)($0.97)ViewListenView Earnings Details
2/24/2016Q4($0.94)($0.99)ViewListenView Earnings Details
8/12/2015Q215($0.68)($0.90)ViewN/AView Earnings Details
5/14/2015Q115($0.56)($0.66)ViewN/AView Earnings Details
2/27/2015Q414($0.44)($1.57)ViewN/AView Earnings Details
11/11/2014Q314($0.40)($0.50)ViewN/AView Earnings Details
8/14/2014Q214($1.23)($4.57)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Sage Therapeutics (NASDAQ:SAGE)
2017 EPS Consensus Estimate: ($6.52)
2018 EPS Consensus Estimate: ($7.37)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($1.58)($1.49)($1.54)
Q2 20173($1.64)($1.50)($1.56)
Q3 20173($1.70)($1.43)($1.58)
Q4 20173($2.19)($1.53)($1.84)
Q1 20182($1.79)($1.75)($1.77)
Q2 20182($1.87)($1.79)($1.83)
Q3 20182($1.91)($1.83)($1.87)
Q4 20182($1.95)($1.85)($1.90)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Sage Therapeutics (NASDAQ:SAGE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Sage Therapeutics (NASDAQ SAGE)

Insider Ownership Percentage: 6.10%
Insider Trades by Quarter for Sage Therapeutics (NASDAQ:SAGE)
Institutional Ownership by Quarter for Sage Therapeutics (NASDAQ:SAGE)

Insider Trades by Quarter for Sage Therapeutics (NASDAQ SAGE)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/13/2017Kimi IguchiCFOSell10,000$53.92$539,200.00View SEC Filing  
11/17/2016Kimi IguchiCFOSell4,000$51.77$207,080.00View SEC Filing  
11/11/2016Kimi IguchiCFOSell1,500$50.59$75,885.00View SEC Filing  
9/7/2016Kimi IguchiCFOSell2,500$40.93$102,325.00View SEC Filing  
7/12/2016Albert RobichaudInsiderSell22,000$40.00$880,000.00View SEC Filing  
7/12/2016Kimi IguchiCFOSell5,000$49.55$247,750.00View SEC Filing  
5/16/2016Kevin P StarrDirectorSell850,000$31.25$26,562,500.00View SEC Filing  
4/19/2016Stephen KanesInsiderSell21,000$38.00$798,000.00View SEC Filing  
1/25/2016Albert RobichaudInsiderSell20,000$40.02$800,400.00View SEC Filing  
9/28/2015Stephen KanesinsiderSell6,000$46.42$278,520.00View SEC Filing  
9/8/2015Kimi IguchiCFOSell3,000$54.84$164,520.00View SEC Filing  
9/1/2015Steven M. PaulDirectorSell20,000$52.41$1,048,200.00View SEC Filing  
8/31/2015Stephen KanesInsiderSell12,000$53.12$637,440.00View SEC Filing  
7/23/2015Jeffrey M JonasInsiderSell3,000$76.79$230,370.00View SEC Filing  
7/6/2015Kimi IguchiCFOSell4,000$68.00$272,000.00View SEC Filing  
7/1/2015Albert RobichaudInsiderSell16,000$72.13$1,154,080.00View SEC Filing  
7/1/2015Steven M PaulDirectorSell20,000$69.40$1,388,000.00View SEC Filing  
6/24/2015Stephen KanesInsiderSell6,000$74.06$444,360.00View SEC Filing  
6/16/2015Jeffrey M JonasInsiderSell198,600$77.36$15,363,696.00View SEC Filing  
6/8/2015Thomas AndersonInsiderSell5,500$79.65$438,075.00View SEC Filing  
6/1/2015Albert RobichaudInsiderSell16,000$72.80$1,164,800.00View SEC Filing  
6/1/2015Steven M PaulDirectorSell20,000$72.34$1,446,800.00View SEC Filing  
2/25/2015Stephen KanesInsiderSell6,000$42.05$252,300.00View SEC Filing  
1/26/2015Stephen KanesInsiderSell6,000$37.29$223,740.00View SEC Filing  
7/23/2014James M FratesDirectorBuy5,000$18.00$90,000.00View SEC Filing  
7/23/2014Stephen KanesInsiderBuy3,000$18.00$54,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Sage Therapeutics (NASDAQ SAGE)

Source:
DateHeadline
Sage Therapeutics, Inc. (SAGE) Rating Reiterated by BMO Capital MarketsSage Therapeutics, Inc. (SAGE) Rating Reiterated by BMO Capital Markets
www.americanbankingnews.com - November 18 at 12:20 PM
Sage Therapeutics Announces Closing of $345 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional SharesSage Therapeutics Announces Closing of $345 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares
finance.yahoo.com - November 18 at 11:34 AM
Sage Therapeutics, Inc. (SAGE) Given New $101.00 Price Target at Bank of America CorporationSage Therapeutics, Inc. (SAGE) Given New $101.00 Price Target at Bank of America Corporation
www.americanbankingnews.com - November 16 at 12:42 PM
Sage Therapeutics Prices Public Offering of Common Stock - Business Wire (press release)Sage Therapeutics Prices Public Offering of Common Stock - Business Wire (press release)
www.businesswire.com - November 15 at 7:57 AM
Sage Therapeutics Prices Public Offering of Common StockSage Therapeutics Prices Public Offering of Common Stock
finance.yahoo.com - November 15 at 7:56 AM
BRIEF-Sage Therapeutics announces proposed public offering of common stockBRIEF-Sage Therapeutics announces proposed public offering of common stock
www.reuters.com - November 14 at 7:35 AM
SAGE Therapeutics Inc. (SAGE) Is Heading Lower After Offering AnnouncementSAGE Therapeutics Inc. (SAGE) Is Heading Lower After Offering Announcement
www.rttnews.com - November 14 at 7:35 AM
Sage Therapeutics Announces Proposed Public Offering of Common StockSage Therapeutics Announces Proposed Public Offering of Common Stock
finance.yahoo.com - November 14 at 7:35 AM
Leerink Swann Weighs in on Sage Therapeutics, Inc.s FY2019 Earnings (SAGE)Leerink Swann Weighs in on Sage Therapeutics, Inc.'s FY2019 Earnings (SAGE)
www.americanbankingnews.com - November 13 at 9:58 AM
Sage Therapeutics stock bounces 54% after positive results for depression treatment - MarketWatchSage Therapeutics stock bounces 54% after positive results for depression treatment - MarketWatch
www.marketwatch.com - November 12 at 12:36 PM
Sage Therapeutics, Inc. (SAGE) Given New $100.00 Price Target at Needham & Company LLCSage Therapeutics, Inc. (SAGE) Given New $100.00 Price Target at Needham & Company LLC
www.americanbankingnews.com - November 12 at 11:46 AM
Investors Buy Large Volume of Sage Therapeutics Call Options (SAGE)Investors Buy Large Volume of Sage Therapeutics Call Options (SAGE)
www.americanbankingnews.com - November 12 at 1:56 AM
Chardan Capital Upgrades Sage Therapeutics, Inc. (SAGE) to "Buy"Chardan Capital Upgrades Sage Therapeutics, Inc. (SAGE) to "Buy"
www.americanbankingnews.com - November 10 at 11:24 AM
Zacks: Analysts Anticipate Sage Therapeutics, Inc. (SAGE) Will Announce Earnings of -$1.99 Per ShareZacks: Analysts Anticipate Sage Therapeutics, Inc. (SAGE) Will Announce Earnings of -$1.99 Per Share
www.americanbankingnews.com - November 10 at 10:06 AM
Sage Therapeutics, Inc. (SAGE) Price Target Increased to $109.00 by Analysts at Raymond James Financial, Inc.Sage Therapeutics, Inc. (SAGE) Price Target Increased to $109.00 by Analysts at Raymond James Financial, Inc.
www.americanbankingnews.com - November 9 at 9:34 PM
Sage Therapeutics, Inc. (SAGE) Given New $123.00 Price Target at Leerink SwannSage Therapeutics, Inc. (SAGE) Given New $123.00 Price Target at Leerink Swann
www.americanbankingnews.com - November 9 at 3:42 PM
Sage Therapeutics, Inc. (SAGE) Price Target Raised to $145.00 at Royal Bank Of CanadaSage Therapeutics, Inc. (SAGE) Price Target Raised to $145.00 at Royal Bank Of Canada
www.americanbankingnews.com - November 9 at 3:42 PM
Sage Therapeutics, Inc. (SAGE) Price Target Raised to $105.00Sage Therapeutics, Inc. (SAGE) Price Target Raised to $105.00
www.americanbankingnews.com - November 9 at 3:42 PM
Sage Therapeutics Wins Big in Depression TrialSage Therapeutics Wins Big in Depression Trial
247wallst.com - November 9 at 12:55 PM
SAGE Therapeutics Inc. (SAGE) Is Suring On Phase 3 Study ResultsSAGE Therapeutics Inc. (SAGE) Is Suring On Phase 3 Study Results
www.nasdaq.com - November 9 at 12:55 PM
Sage soars as postpartum depression drug moves closer to approvalSage soars as postpartum depression drug moves closer to approval
www.reuters.com - November 9 at 12:54 PM
Sage Therapeutics Appoints Asha Nayak, M.D., Ph.D., to Board of DirectorsSage Therapeutics Appoints Asha Nayak, M.D., Ph.D., to Board of Directors
finance.yahoo.com - November 9 at 12:54 PM
Sage Therapeutics Announces Brexanolone Achieves Primary Endpoints in Both Phase 3 Clinical Trials in Postpartum DepressionSage Therapeutics Announces Brexanolone Achieves Primary Endpoints in Both Phase 3 Clinical Trials in Postpartum Depression
finance.yahoo.com - November 9 at 12:54 PM
Sage Therapeutics postpartum depression drug meets goal in two trialsSage Therapeutics postpartum depression drug meets goal in two trials
finance.yahoo.com - November 9 at 12:54 PM
Sage Therapeutics to seek approval of postpartum depression drug after trial winSage Therapeutics to seek approval of postpartum depression drug after trial win
finance.yahoo.com - November 9 at 12:54 PM
Sage Therapeutics stock surges 50% on positive trial results in postpartum depressionSage Therapeutics stock surges 50% on positive trial results in postpartum depression
finance.yahoo.com - November 9 at 12:54 PM
New Drug Eases Postpartum Depression In Victory For Tiny Sage TherapeuticsNew Drug Eases Postpartum Depression In Victory For Tiny Sage Therapeutics
finance.yahoo.com - November 9 at 12:54 PM
Sage Therapeutics stock bounces 49% after positive results for depression treatmentSage Therapeutics stock bounces 49% after positive results for depression treatment
finance.yahoo.com - November 9 at 12:54 PM
2 Antidepressant-Focused Biotech Stocks Are Surging Today. Here's Why.2 Antidepressant-Focused Biotech Stocks Are Surging Today. Here's Why.
finance.yahoo.com - November 9 at 12:53 PM
SAGE Therapeutics: Postpartum Depression Play - Seeking AlphaSAGE Therapeutics: Postpartum Depression Play - Seeking Alpha
seekingalpha.com - November 7 at 9:51 AM
Leerink Swann Analysts Boost Earnings Estimates for Sage Therapeutics, Inc. (SAGE)Leerink Swann Analysts Boost Earnings Estimates for Sage Therapeutics, Inc. (SAGE)
www.americanbankingnews.com - November 6 at 3:26 AM
Sage Therapeutics, Inc. to Post FY2017 Earnings of ($7.16) Per Share, SunTrust Banks Forecasts (SAGE)Sage Therapeutics, Inc. to Post FY2017 Earnings of ($7.16) Per Share, SunTrust Banks Forecasts (SAGE)
www.americanbankingnews.com - November 6 at 3:26 AM
Sage Therapeutics, Inc. (SAGE) Receives Consensus Rating of "Buy" from BrokeragesSage Therapeutics, Inc. (SAGE) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - November 5 at 3:46 AM
Sage Therapeutics Announces Third Quarter 2017 Financial Results and Provides Pipeline Update - Business Wire (press release)Sage Therapeutics Announces Third Quarter 2017 Financial Results and Provides Pipeline Update - Business Wire (press release)
www.businesswire.com - November 4 at 1:09 PM
SAGE Therapeutics, Inc. to Host Earnings CallSAGE Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - November 4 at 1:09 PM
Sage Therapeutics Announces Third Quarter 2017 Financial Results and Provides Pipeline UpdateSage Therapeutics Announces Third Quarter 2017 Financial Results and Provides Pipeline Update
finance.yahoo.com - November 4 at 1:09 PM
Sage Therapeutics reports 3Q lossSage Therapeutics reports 3Q loss
finance.yahoo.com - November 4 at 1:09 PM
Edited Transcript of SAGE earnings conference call or presentation 2-Nov-17 12:00pm GMTEdited Transcript of SAGE earnings conference call or presentation 2-Nov-17 12:00pm GMT
finance.yahoo.com - November 4 at 1:09 PM
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
finance.yahoo.com - November 4 at 1:09 PM
Royal Bank Of Canada Boosts Sage Therapeutics, Inc. (SAGE) Price Target to $120.00Royal Bank Of Canada Boosts Sage Therapeutics, Inc. (SAGE) Price Target to $120.00
www.americanbankingnews.com - November 2 at 6:28 PM
Sage Therapeutics, Inc. (SAGE) Releases Quarterly  Earnings Results, Beats Expectations By $0.01 EPSSage Therapeutics, Inc. (SAGE) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS
www.americanbankingnews.com - November 2 at 2:02 PM
Wall Street Cools on Biotech - BloombergWall Street Cools on Biotech - Bloomberg
www.bloomberg.com - November 1 at 8:31 PM
Marinus Pharmaceuticals: The Next Big Thing In CNSMarinus Pharmaceuticals: The Next Big Thing In CNS
seekingalpha.com - November 1 at 8:26 AM
Crescendo Bioscience Announces Six Presentations At The American College Of Rheumatology 2017 Annual MeetingCrescendo Bioscience Announces Six Presentations At The American College Of Rheumatology 2017 Annual Meeting
www.thestreet.com - October 31 at 9:06 AM
BMO Capital Markets Reiterates "Buy" Rating for Sage Therapeutics, Inc. (SAGE)BMO Capital Markets Reiterates "Buy" Rating for Sage Therapeutics, Inc. (SAGE)
www.americanbankingnews.com - October 28 at 12:50 PM
Implied Volatility Surging for Sage Therapeutics (SAGE) Stock Options - NasdaqImplied Volatility Surging for Sage Therapeutics (SAGE) Stock Options - Nasdaq
www.nasdaq.com - October 27 at 3:52 PM
Implied Volatility Surging for Sage Therapeutics (SAGE) Stock OptionsImplied Volatility Surging for Sage Therapeutics (SAGE) Stock Options
finance.yahoo.com - October 27 at 3:52 PM
Oversold Conditions For Sage Therapeutics (SAGE)Oversold Conditions For Sage Therapeutics (SAGE)
www.nasdaq.com - October 24 at 9:39 AM
Sage Therapeutics to Report Third Quarter 2017 Financial Results on Thursday, November 2, 2017Sage Therapeutics to Report Third Quarter 2017 Financial Results on Thursday, November 2, 2017
finance.yahoo.com - October 24 at 9:39 AM
Sage Therapeutics, Inc. (SAGE) Expected to Announce Earnings of -$1.95 Per ShareSage Therapeutics, Inc. (SAGE) Expected to Announce Earnings of -$1.95 Per Share
www.americanbankingnews.com - October 21 at 6:06 PM

Social Media

Financials

Chart

Sage Therapeutics (NASDAQ SAGE) Chart for Sunday, November, 19, 2017
Loading chart…

This page was last updated on 11/19/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.